IllnessCYP2D6 analysis before Tamoxifen therapy

Summary

Short information

The speed of the metabolization by CYP450 2D6 co-determines the parmacologocal level in the Tamoxifen therapy. The genetic CYP2D6 variants are determined in a curated manner.

PT7531

Number of genes

1 Accredited laboratory test

Examined sequence length

1,5 kb (Core-/Core-canditate-Genes)
- (Extended panel: incl. additional genes)

Analysis Duration

on request

Material

EDTA-anticoagulated blood (3-5 ml)

Diagnostic indications

Sanger

Gene panel

Selected genes

Name	Exon Length (bp)	OMIM-G	Referenz-Seq.	Heredity
CYP2D6	1494	124030	NM_000106.6	AR

Informations about the disease

Clinical Comment

illness_clinical_commment_PT7531

Synonyms

Allelic: Cerdelga-Therapie - Morbus Gaucher
Allelic: Codeine sensitivity
Allelic: Debrisoquine sensitivity
Cytochrom P450 2D6
Fremdsubstanz-Metabolisierer (Opiode, trizyklische Antidepressiva, Neuroleptika, Beta-Blocker etc.)
Poor and/or ultrarapid metabolism of several drugs, including debrisoquine, sparteine, nortriptyline

Heredity, heredity patterns etc.

OMIM-Ps

124030

ICD10 Code

Bioinformatics and clinical interpretation

No text defined